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Although the microbiota has been shown to drive
production of interleukin-17A (IL-17A) from T helper
17 cells to promote cell proliferation and tumor
growth in colorectal cancer, the molecular mecha-
nisms for microbiota-mediated regulation of tumori-
genesis are largely unknown. Here, we found that
the innate-like cytokine IL-17Cwas upregulated in hu-
man colorectal cancers and inmouse intestinal tumor
models. Alterations in the microbiota drove IL-17C
upregulation specifically in intestinal epithelial cells
(IECs) through Toll-like receptor (TLR)-MyD88-
dependent signaling during intestinal tumorigenesis.
Microbiota-driven IL-17C induced Bcl-2 and Bcl-xL
expression in IECs in an autocrinemanner to promote
cell survival and tumorigenesis in both chemically
induced and spontaneous intestinal tumor models.
Thus, IL-17C promotes cancer development by
increasing IEC survival, and the microbiota can
mediate cancer pathogenesis through regulation of
IL-17C.
INTRODUCTION
Colorectal cancer (CRC) represents the third most prevalent
malignancy and one of the major killers of cancer patients world-
wide (Grivennikov, 2013). Recent studies have demonstrated
that inflammation promotes the development of a variety of
cancers, including colitis-associated cancer (CAC) (Grivennikov,
2013; Mantovani et al., 2008). One common mouse model for
CAC is chemically induced colon cancer by administration of
the carcinogen azoxymethane (AOM) plus dextran sodium sul-
fate (DSS); in this model, DSS-induced colitis greatly promotes
AOM-mediated cancer development (Okayasu et al., 1996).
The Apcmin/+ mouse strain is a well-recognized spontaneous
CRC model, which develops intestinal cancer as a result of the140 Immunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc.complete loss of heterozygosity of the tumor-suppressor gene
Apc (Rakoff-Nahoum and Medzhitov, 2007; Su et al., 1992).
The intestinal microbiota has been shown to contribute to the
development of CRC or CAC (Grivennikov, 2013). Dysregulation
or altered localization of the gut microbiota due to epithelium
damage activates innate immunity to induce inflammation
through pathogen-recognition receptors such as Toll-like recep-
tors (TLRs) (Grivennikov, 2013; Grivennikov et al., 2012; Rakoff-
Nahoum et al., 2004). Activation of innate immune cells results in
the production of proinflammatory cytokines such as tumor ne-
crosis factor a (TNFa) and interleukin-6 (IL-6), which activate
the transcription factors NF-kB and STAT3, respectively, in
intestinal epithelial cells. Both NF-kB and STAT3, which are acti-
vated in CAC, promote tumor development by inducing genes
for cell survival and proliferation (Bollrath et al., 2009; Greten
et al., 2004; Grivennikov et al., 2009; Grivennikov et al., 2010).
Innate immunity promotes the development of adaptive immu-
nity. The recently discovered T helper 17 (Th17) cells have been
found to play a critical role in promoting cancer (Grivennikov
et al., 2010; Langowski et al., 2006). Genetic deletion of IL-23,
a cytokine critical for promoting Th17 cell development, dramat-
ically reduced colon cancer development in the CPC-Apcmin/+
mouse CRC model, which develops tumors mainly in the distal
colon (Grivennikov et al., 2012). Th17 cells secrete characteristic
cytokines such as IL-17A, IL-17F, and IL-22 (Grivennikov et al.,
2010; Zhu and Qian, 2012). All three Th17 cytokines are required
for intestinal tumorigenesis in the Apcmin/+ mouse model (Chae
and Bothwell, 2011; Chae et al., 2010; Huber et al., 2012).
IL-17A also promotes tumor development in other cancer
models (Song and Qian, 2013b).
In addition to including IL-17A and IL-17F, IL-17 family cyto-
kines contain four other members: IL-17B, IL-17C, IL-17D, and
IL-17E (Gaffen, 2009). The IL-17 receptor family consists of five
members: IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE
(Gaffen, 2009). IL-17A and IL-17F bind to the IL-17RC-IL-17RA
heterodimer complex and induce inflammatory genes involved
in host defense and pathogenesis of autoimmune disease (Song
and Qian, 2013b; Zhu and Qian, 2012). IL-17A signaling is the
best studied member of the IL-17 family and is tightly regulated
(Shi et al., 2011; Song and Qian, 2013a; Zhu et al., 2010; Zhu
Figure 1. IL-17C Is Upregulated in Human CRCs and Mouse Intestinal Cancer Models
(A) Quantitative mRNA expression of IL-17C, IL-17A, and IL-23p19 in colorectal tumors (T) or matching normal colons (N) from human CRC patients (n = 24).
(B) Immunoblot analysis of IL-17C expression in six paired colorectal tumors (T) or matching normal colons (N) from human CRC patients.
(C and D) Quantitative mRNA expression of IL-17C, IL-17A, and IL-23p19 in intestinal tumors (T) or normal control intestines (N) from a mouse model of CAC
induced by AOM plus DSS (C) or from Apcmin/+ mice (D) (n = 4).
(E and F) Immunoblot analysis of IL-17C expression in intestinal tumors (T) or normal control intestines (N) from the CAC model (E) or Apcmin/+ mice (F) as in (C)
and (D).
(G and H) Quantitative mRNA expression of IL-17C or IL-17A in the isolated IECs or LPLs of intestinal tumors (T) or normal control intestines (N) from the CAC
model (G) or Apcmin/+ mice (H) as in (C) and (D) (n = 4).
Data are representative of three independent experiments (mean ± SEM in A, C, D, G, and H). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test.
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ligand for the orphan receptor IL-17REandmediates host defense
and autoimmune inflammation (Chang et al., 2011; Ramirez-Car-
rozzi et al., 2011; Song et al., 2011). However, it is unclear whether
IL-17C is involved in the regulation of cancer development.
Although it is known that the microbiota activates innate
immune cells and promotes adaptive Th17 cell development
to lead to the production of tumor-promoting cytokines, the
exact mechanisms through which the microbiota contributes to
CRC development are largely unknown. Here, we found that
microbiota-driven IL-17C promotes colon cancer development
by protecting intestinal epithelial cells (IECs) from apoptosis.
IL-17C and IL-17Awere differentially regulated and played differ-
ential roles in intestinal tumorigenesis. Our study has discovered
a mechanism for microbiota-mediated cancer pathogenesis
through the regulation of IL-17C.RESULTS
IL-17C Is Upregulated in Intestinal Cancers
IL-17A is upregulated in human CRC specimens and contributes
to CRC development (Grivennikov et al., 2012; Tosolini et al.,
2011). During a survey of human CRC specimens, we found
that unlike in normal controls, IL-17C mRNA was upregulated
in human CRC samples; similar upregulation was noted for
IL-17A and IL-23, a cytokine that promotes Th17 cell develop-
ment and IL-17A production (Figure 1A). IL-17C was also upre-
gulated in human CRC (Figure 1B). To determine whether
IL-17C is regulated during tumorigenesis, we used mouse
models mimicking human CRC development. Unlike in normal
colonic tissue samples, the amount of mRNA encoding IL-17C
was upregulated in distal colon tumors from the CAC mouse
model induced by AOM plus DSS; similar upregulation wasImmunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc. 141
Figure 2. IL-17C Signaling Is Required for
Tumorigenesis in a Mouse Model of CAC
(A and B) Macroscopic view (A) and hematoxylin
and eosin (H&E) histology (B) of the representative
mouse colons from WT or Il17re/ mice on day
80 of the CAC model. There was no significant
difference in the colon length between WT and
Il17re/ mice in (A). Photomicrographs of histol-
ogy are shown at 1003 magnification.
(C and D) Colon tumor number (C) and tumor load
(D) fromWT (n = 7) and Il17re/ (n = 5)mice on day
80 of the CAC model.
(E) Histogram showing the size distribution of
tumors from WT and Il17re/ mice.
(F) H&E histology of the representative mouse
colons from the following BM-transplanted mice
on day 80 of the CAC model: WT/ WT (n = 7),
Il17re//WT (n = 6),WT/ Il17re/ (n = 6), and
Il17re// Il17re/ mice (n = 5) (1003 magnifi-
cation).
(G and H) The colon tumor number (G) and tumor
load (H) from the transplanted mice as shown
in (F).
Data are representative of three independent
experiments (mean ± SEM in C, D, G, and H).
*p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t
test. See also Figure S1.
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IL-17C Mediates Microbiota-Driven Tumorigenesisobserved for IL-17A and IL-23 (Figure 1C). Comparable results
were also observed in distal small intestinal tumors of Apcmin/+
mice, a spontaneous intestinal carcinogenesismodel (Figure 1D).
IL-17C was also upregulated in both models (Figures 1E and 1F).
Thus, IL-17C is upregulated in human CRC and mouse models
of CRC.
Th17 cells are the major cellular source of IL-17A secretion
during colon tumor formation (Grivennikov et al., 2012; Tosolini
et al., 2011). To reveal the cellular source of upregulated
IL-17C, we separated IECs and laminar propria lymphocytes
(LPLs) from CAC tumors to determine the expression of
IL-17C and IL-17A. In the CAC mouse model, IL-17C was spe-
cifically upregulated in IECs, whereas IL-17A was produced by
LPLs (Figure 1G). Similarly, IL-17C and IL-17A were produced
by IECs and LPLs, respectively, in the small intestinal
tumors of Apcmin/+ mice (Figure 1H). These data suggest that
IL-17C and IL-17A are differentially regulated during CRC
development.
IL-17C Signaling Is Essential for Intestinal
Tumorigenesis
Given that IL-17C was upregulated in colon cancers, we next
asked whether IL-17C has a role in colon tumorigenesis in the
CAC mouse model induced by AOM plus DSS. Deficiency of
IL-17RE, a specific receptor of IL-17C, dramatically reduced
colon tumor formation (Figure 2A). Histology staining showed
that the colon tumor size was greatly decreased in Il17re/
mice (Figure 2B). Both tumor number and tumor load were signif-
icantly diminished in Il17re/mice (Figures 2C and 2D). Further-
more, analyses of tumor-size distribution showed that most of
the tumors in the Il17re/ mice were small in size (Figure 2E).
Because we found that IL-17C and IL-17A were differentially142 Immunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc.regulated by different cellular sources (Figure 1), we then sought
to determine the contribution of gut local resident cells versus
infiltrating immune cells in IL-17C-driven colon tumorigenesis
by bone marrow (BM) transplantation experiments. Irradiated
wild-type (WT) recipients reconstituted with WT or Il17re/
BM-derived cells had similar tumor size (Figure 2F), tumor
number (Figure 2G), and tumor load (Figure 2H), suggesting
that gut-infiltrating immune cells are not important for IL-17C-
mediated tumor promotion. However, compared to the reconsti-
tuted WT recipient mice, irradiated Il17re/ recipient mice
transplanted with WT or Il17re/ BM-derived cells showed
reduced tumor size (Figure 2F), tumor number (Figure 2G), and
tumor load (Figure 2H), indicating that gut local resident cells
are critical for the IL-17C-mediated promoting effect on colon
tumorigenesis. To determine whether IL-17C has a role in pro-
moting spontaneous tumorigenesis, we bred Il17re/ mice
with Apcmin/+ mice. Deficiency of IL-17C signaling in Apcmin/+
mice dramatically impaired spontaneous small intestinal tumor
development (Figure 3A). The spontaneous small intestinal
tumor size was also dramatically decreased upon genetic abla-
tion of Il17re (Figure 3B). Both tumor number (Figures 3C and
3D) and tumor load (Figures 3E and 3F) were significantly
reduced in the small intestine or colon upon deficiency of
IL-17C signaling. As in the induced CAC mouse model, most
of the tumors were small adenomas in Apcmin/+ Il17re/ mice
(Figure 3G). Consistent with severely reduced intestinal tumor
development, the anemia or thymus atrophy in Apcmin/+ mice
was significantly ameliorated to almost normal upon IL-17RE
deficiency (Figures 3H and 3I). The transcription factors NF-kB
and STAT3 are often activated to promote tumorigenesis
(Grivennikov and Karin, 2010). We found that activation
of both transcription factors, as well as the expression of
Figure 3. IL-17C Signaling Is Essential for
the Spontaneous Tumor Development in
Apcmin/+ Mice
(A and B) Macroscopic view (A) and H&E histology
(B) of the representative mouse small intestines
from 20-week-old Apcmin/+ or Apcmin/+ Il17re/
mice. Photomicrographs of histology are shown at
1003 magnification.
(C–F) Tumor number (C and D) and tumor load
(E and F) from the small intestines or colons of
20-week-old Apcmin/+ (n = 16) or Apcmin/+ Il17re/
(n = 14) mice.
(G) Histogram showing the size distribution of
tumors from the small intestines of 20-week-old
Apcmin/+ or Apcmin/+ Il17re/ mice.
(H and I) Hematocrit (H) and thymus weight (I) of
20-week-old Apcmin/+ (n = 13), Apcmin/+ Il17re/
(n = 11), Il17re/ (n = 7), or WT (n = 7) mice.
Data represent the mean ± SEM in (C)–(F), (H), and
(I). **p < 0.01, ***p < 0.001 by Student’s t test. See
also Figure S1.
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tumors of Il17re/ mice (Figure S1, available online). Thus, our
data suggest that IL-17C signaling is critical for intestinal tumor
development.
IL-17C Promotes Tumorigenesis by Increasing IEC
Survival
To determine whether inflammation is the primary factor
causing IL-17C to promote tumorigenesis, we checked the in-
flammatory microenvironment before tumor formation. Instead
of showing moderated inflammatory pathogenesis, Il17re/
mice showed more weight loss, enhanced colon inflammation
and destruction, shorter colon length, and increased bleeding
and stool scores at the early stage of the CAC model (Figures
S2A–S2D). These data are consistent with the reported
enhanced inflammation phenotype of Il17re- or Il17c-deficient
mice in the DSS-induced colitis model (Ramirez-Carrozzi
et al., 2011; Reynolds et al., 2012). In contrast to showing a
reduced tumor proinflammatory microenvironment at day 80
of the CAC model, Il17re-deficient colons showed elevated
activation of NF-kB and STAT3 and increased production of
proinflammatory genes at day 15 (Figures S2E and S2F).
However, the increased production of proinflammatory genes
was lost after the antibiotic treatments to remove the gut micro-
biota (Figure S2F). Furthermore, the inflammation-promoting
E.coli, but not Lactobacillus, outgrew upon DSS treatment in
Il17re/ mice compared to in WT mice (Figures S2G and
S2H), suggesting that IL-17C signaling controls intestinal
microbiota homeostasis to regulate colitis. These data also
suggest that inflammation is not the primary factor causing
IL-17C to promote tumor development, although IL-17C mightImmunity 40, 140–152promote inflammation supporting tumor
formation at late stages of tumor
development.
To understand why IL-17C promotes
tumorigenesis, we looked at colon cell
proliferation by Ki67 and BrdU staining
or cell apoptosis by TUNEL assay. Atday 15 of the CAC model, IEC proliferation was not obviously
changed in Il17re/ mice (Figures 4A–4D). However, IEC
apoptosis was dramatically increased in Il17re/ mice (Figures
4E and 4F) but unchanged in Il17a/mice (Figures 4G and 4H).
The reason for the unaltered cell proliferation in Il17re/ IECs at
day 15 might have been due to the balance of increased inflam-
mation and reduced cell survival. We then examined the expres-
sion of antiapoptotic and proapoptotic genes and found that
expression of the prosurvival genes encoding Bcl-xL and Bcl-2
was reduced in Il17re/ colons at day 15 of the CAC model
(Figure 4I). No changes were detected in cyclin D1 expression,
consistent with the observation that cell proliferation was
normal in Il17re/ colons (Figure 4I). In contrast, the expression
of Bcl-xL and Bcl-2 was unchanged, whereas that of cyclin D1
was reduced in the colons of Il17a/ mice (Figure 4J), which
was consistent with a previous study demonstrating that
IL-17A signaling is critical for cell proliferation during CAC
(Hyun et al., 2012). The amounts of Bcl-xL and Bcl-2 were also
dramatically reduced in Il17re/ colons (Figure 4K). The expres-
sion of Bcl-xL and Bcl-2 was impaired in IECs, but not in LPLs,
isolated from Il17re/ colons (Figures 4L and 4M), indicating
that unlike IL-17A, IL-17C functions as an autocrine cytokine to
promote IEC survival during the early stage of tumorigenesis.
Similar to in the early stage of CAC development, cell
apoptosis was greatly elevated in Il17re/ colon tumors at
day 80 of the CAC model (Figures S3A and S3B). Consistently,
mRNA and protein expression of Bcl-xL and Bcl-2 was severely
reduced in Il17re/ colon tumors (Figures S3C and S3D). Cyclin
D1 expression was also reduced in the Il17re/ colon tumors
(Figure S3C). Similarly, IL-17RE deficiency led to reduced cell
survival and the expression of the survival genes at a late stage, January 16, 2014 ª2014 Elsevier Inc. 143
Figure 4. IL-17C Signaling Protects Colon Epithelium from Apoptosis at an Early Stage of CAC
(A–D) Ki67 staining (A) and BrdU (C) incorporation into intestinal epithelial cells of the representative colons fromWT or Il17re/mice on day 15 of the CACmodel
(4003 magnification). The number of proliferating cells per crypt determined by Ki67 (B) or BrdU (D) of the representative colons is shown as in (A) and (C).
(E–H) TUNEL staining of the representative colons fromWT, Il17re/ (E), or Il17a/ (G) mice on day 15 of the CACmodel (4003magnification) and the number of
apoptotic cells per field (F and H) of the representative colons as in (E) and (G).
(I and J) Quantitative mRNA expression of Bcl-2, Bcl-xL, BAK1, BAX, and cyclin D1 in the colons of WT or Il17re
/ mice (n = 4) (I) and in the colons of WT or
Il17a/ mice (n = 4) (J) on day 15 of the CAC model.
(K–M) Immunoblot analysis of Bcl-xL, Bcl-2, BAK1, and BAX in the colons (K), IECs (L), and LPLs (M) of WT or Il17re
/ mice on day 15 of the CAC model.
Data are representative of three independent experiments (mean ± SEM in B, D, F, and H–J). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. See also Figures
S2 and S3.
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IL-17C Mediates Microbiota-Driven Tumorigenesisof tumor development (at the age of 20 weeks) in Apcmin/+
mice (Figures S3E–S3H). Together, our data suggest that
IL-17C induces prolonged IEC survival to promote intestinal
tumorigenesis.
IL-17C Promotes Tumorigenesis through Induction of
Bcl-xL and Bcl-2 Expression in IECs
To determine whether IL-17C induces the expression of Bcl-xL
and Bcl-2 during early colon tumor development, we examined
the expression kinetics of IL-17C versus Bcl-xL and Bcl-2 during
the early stage of the CACmodel (Figure 5A). IL-17C, Bcl-xL, and
Bcl-2 were expressed in high amounts in the colon (Figure 5B) or
in isolated IECs (Figure S4A) as early as 9 days after treatment144 Immunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc.with AOM plus DSS, at which time point the body weight of
mice had not decreased (Figure 5A). In contrast, IL-17A was
induced at day 21, whereas IL-23 was highly induced at day 9
in both colons (Figure 5B) and isolated LPLs (Figure S4B), which
is consistent with the IL-23- mediated promotion of Th17 devel-
opment for IL-17A production. Next, we utilized an adenoviral
system to express IL-17C in mice and found that IL-17C induced
the expression of Bcl-xL and Bcl-2 in the colons of WT mice, but
not Il17re/ mice (Figure 5C). We then isolated IECs from WT
and Il17re/ mice and treated the cells with recombinant
IL-17C in vitro and found that IL-17C induced the expression
of Bcl-xL andBcl-2 inWT IECs, but not Il17re
/ IECs (Figure 5D).
To determine whether IL-17C-mediated induction of Bcl-2 and
Figure 5. IL-17C Induces the Expression of Bcl-xL and Bcl-2 in IECs to Promote Tumor Formation
(A) Body-weight change of C57/BL6 mice during the early stage of the CAC model (n = 3 or 4 for each time point).
(B) Quantitative mRNA expression of IL-17C, IL-23p19, IL-17A, Bcl-2, and Bcl-xL in the colons during the early stage of the CAC model (n = 4).
(C) Quantitative mRNA expression of Bcl-2 and Bcl-xL in the colons of WT or Il17re
/ mice treated with IL-17C-expressing adenovirus (Adv-IL-17C) or empty
control virus (Adv-EV) (n = 4).
(D) Quantitative mRNA expression of Bcl-2 and Bcl-xL in cultured primary WT or Il17re
/ IECs stimulated by IL-17C (n = 4).
(E) Quantitative mRNA expression of Bcl-2 and Bcl-xL in the colons of WT or Il17re
/ mice either left untreated (N) or treated with AOM plus DSS for tumori-
genesis (CAC). The empty control virus (Adv-EV) or Bcl-2- and Bcl-xL-expressing adenoviruses (Adv-Bcl-2 and Adv-Bcl-xL, respectively) were delivered to the
mice multiple times during the treatment (n = 4).
(F) H&E histology of the representative mouse colon tumors of WT or Il17re/ mice in the CAC model as treated in (E) (1003 magnification).
(G) Tumor number and load of the mouse colon tumors from WT or Il17re/ mice in CAC model as treated in (E) (n = 5–7 for each group).
Data are representative of two (E–G) or three (A–D) independent experiments (mean ± SEM in A–E and G). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test.
See also Figure S4.
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Figure 6. The Microbiota Is Required for IL-17C Induction during Intestinal Tumorigenesis
(A and B) Quantitative mRNA expression of IL-17C in the colons (A) or IECs (B) of C57/BL6 mice treated with or without the cocktail of antibiotics (Abx) and then
stimulated with AOM plus DSS for 15 days (n = 4).
(C and D) Quantitative mRNA expression of IL-17C in the colons (C) or IECs (D) of WT or Myd88/ mice stimulated with AOM plus DSS for 15 days (n = 4).
(E) QuantitativemRNA expression of IL-17C in the colons of the following BM-transplantedmice on day 15 of the CACmodel: WT/WT (n = 4),Myd88//WT
(n = 4), WT/ Myd88/ (n = 4), and Myd88// Myd88/ (n = 4).
(F) Quantitative mRNA expression of IL-17C in the colons of WT, Casp1/, or Asc/ mice stimulated as in (C) (n = 4).
(G and H) Quantitative mRNA expression of IL-17C in the normal colons (N) or colon tumors (T) (G) or IECs (H) of C57/BL6 mice treated with or without Abx and
then treated with the conditions for the CAC model (n = 4).
(legend continued on next page)
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IL-17C Mediates Microbiota-Driven TumorigenesisBcl-xL is important for IL-17C to promote tumorigenesis, we
ectopically expressed Bcl-2 and Bcl-xL in Il17re
/ mice in vivo
through an adenoviral system (Figure 5E). Restoration of Bcl-2
and Bcl-xL expression in Il17re
/ mice recovered the colon
tumor size, number, and load (Figures 5F and 5G). These data
indicate that IL-17C directly induces the expression of Bcl-xL
and Bcl-2 in IECs to promote cell survival and colon tumor
development.
The Microbiota Drives IL-17C Production during
Intestinal Tumorigenesis
Antibiotic-mediated removal of the gut microbiota has been
reported to block IL-17A expression during colon tumor devel-
opment (Grivennikov et al., 2012). We also found that after treat-
ment with a cocktail of antibiotics to remove the gut microbiota
(data not shown), the induction of IL-23 and IL-17A was blocked
in both colons and LPLs at day 15 of theCACmodel (Figures S5A
and S5B). The antibiotic treatment also blocked the induction of
IL-17C in both colons and IECs (Figures 6A and 6B), suggesting
that the microbiota is critical for IL-17C induction. To see
whether IL-17C is regulated by IL-23, we stimulated IL-23R-
expressing LPLs, mesenteric lymph node cells, and Th17 cells
with IL-23 and found that IL-23 induced IL-17A expression, but
not IL-17C expression, in those cells (Figures S6A–S6C). IL-23
did not induce IL-17C expression in IECs, which had low
IL-23R expression (Figure S6D). Consistent with the in vitro re-
sults, IL-23R antibody blockage in mice reduced IL-17A induc-
tion. However, the blockage did not reduce but rather increased
IL-17C induction (Figure S6E). The Th17 cytokine IL-22 did not
induce IL-17C expression in IECs (Figure S6D). Whereas
IL-17A weakly induced IL-17C expression in IECs (Figure S6D),
IL-17A deficiency in vivo did not reduce but rather increased
IL-17C induction (Figure S6F). These data suggest that the
hematopoietic IL-23-Th17 axis is not responsible for IL-17C in-
duction at day 15 of the CAC model. MyD88, a key adaptor in
TLR-mediated signaling, has been reported to be crucial for mi-
crobiota-driven IL-17A production during colon tumor develop-
ment (Grivennikov et al., 2012). As expected, we found that
MyD88 was essential for the induction of IL-23 and IL-17A in co-
lons (Figure S5C) at day 15 of the CAC model. We found that
MyD88 was also critical for IL-17C induction in both colons
and IECs in the same sets of experiments (Figures 6C and 6D).
We then performed BMchimera experiments and found that irra-
diated Myd88/ recipient mice reconstituted with WT or
Myd88/ BM had reduced IL-17C induction and that irradiated(I and J) Quantitative mRNA expression of IL-17C in the normal small intestines (N)
with or without Abx (n = 6).
(K) Quantitative PCR analysis of 16S rDNA of Enterobacteriaceae and E. coli in th
intestine at day 0 or 15 of the CAC model (n = 6).
(L andM) Bacterial titers of Enterobacteriaceae (L) (n = 6) and E. coli (M) (n = 5) in th
(N) LPS staining of the representative colons from WT mice at day 0 or 15 of the
(O) Quantitative mRNA expression of IL-17C in the colons of the Abx-treated mi
Flagellin (FLA), or 1010 CFU of E. coli (n = 4).
(P) QuantitativemRNA expression of IL-17C in the colons of germ-free (GF) mice, w
E. coli (n = 3).
(Q) Quantitative mRNA expression of IL-17C in human colonic epithelial cell l
Enterobacteriaceae or E. coli for 0 or 3 hr.
Data are representative of two (N–P) or three (A–M andQ) independent experiment
t test. See also Figures S5–S7.WT recipient mice reconstituted with WT or Myd88/ BM had
similar levels of IL-17C induction (Figure 6E), suggesting that
the microbiota directly induces IL-17C expression in IECs
through MyD88. In contrast, MyD88 expression in the BM-
derived cells was required for IL-17A induction (Figure S5D).
These data further confirm that IL-17C and IL-17A are differen-
tially regulated. Given that MyD88 is also utilized by both IL-1b
and IL-18 signaling, we next determined the contribution of these
two pathways on IL-17C production by analyzing Asc- or
caspase 1 (Casp1)-deficient mice, in which the processing of
pre-IL-1b and pre-IL-18 to mature forms was blocked (Davis
et al., 2011). As expected, the expression of IL-17Awas impaired
in the colons of those deficient mice at day 15 of the CAC model
(Figure S5E), consistent with the role of IL-1b in promoting Th17
differentiation (Chung et al., 2009). Unexpectedly, IL-17C
expression was not altered in the colons of Asc - or Casp1-defi-
cient mice (Figure 6F), indicating that IL-17C production is
merely controlled by TLR-MyD88 signaling. Although IL-17C
was upregulated in the CAC colon tumors, the removal of the
gut microbiota by a cocktail of antibiotics (data not shown)
blocked the upregulation of IL-17C in the colon tumors and the
tumor-derived IECs (Figures 6G and 6H). The antibiotic treat-
ment also inhibited the induction of IL-23 and IL-17A in both
colons and LPLs (Figures S5F and S5G). Similar to the blockage
of IL-17A upregulation (Figures S5H and S5I), antibiotic treat-
ment also removed the gut microbiota in Apcmin/+ mice (data
not shown) and subsequently prevented the upregulation of IL-
17C in the intestine tumors and tumor-derived IECs (Figures 6I
and 6J) in those mice. These data suggest that IL-17C upregula-
tion is driven by the microbiota through TLR-MyD88 signaling
during colon tumorigenesis.
To survey which gut commensals are responsible for IL-17C
induction during CRC development, we used 16S rDNA real-
time PCR to examine four major intestinal bacterial phyla—Bac-
teroidetes, Firmicutes, Actinobacteria, and Proteobacteria—as
well as their representative classes, genera, or species. The
numbers of Firmicutes and Actinobacteria were not significantly
altered either in luminal specimens or at mucosal surfaces of
colons and small intestines at day 15 of the CAC induction
(Figure S7A). However, the bacterial numbers of the Bacteroi-
detes phylum and Bacteroides genus of the phylumwere slightly
decreased in the luminal specimens after the induction (Fig-
ure S7A). In contrast, the number of Proteobacteria phylum bac-
teria was dramatically increased both in the luminal specimens
and at the mucosal surfaces (Figure S7A). The number ofor small intestinal tumors (T) (I) or IECs (J) of 20-week-oldApcmin/+ mice treated
e intestinal luminal specimens (feces) or the mucosal surfaces of colon or small
e fecal, colon, or small intestinal homogenates at day 0 or 15 of the CACmodel.
CAC model (2003 magnification).
ce, which were treated with or without DSS and then administrated with LPS,
hichwere treated with or without DSS and then administrated with 1010 CFU of
ines (HT29 and DLD1) or in-vitro-cultured mouse primary IECs treated with
s (mean ± SEM in A–M andO–Q). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s
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Alphaproteobacteria, Betaproteobacteria, and Epsilonproteo-
bacteria of the phylum were not (Figure S7A). The number of
Enterobacteriaceae, one family of the Gammaproteobacteria
class, increased after induction (Figure 6K). E. coli belongs to
the Enterobacteriaceae family, is associated with human inflam-
matory bowel disease and CRC, andmight contribute to disease
pathogenesis (Arthur et al., 2012; Kim et al., 2005; Martin et al.,
2004). The number of E. coliwas also increased both in the intes-
tinal luminal specimens and at the mucosal surfaces (Figure 6K).
We further found that DSS, instead of AOM, resulted in the
outgrowth of the microbiota and the production of proinflamma-
tory genes in the CAC model (Figures S7B and S7C). We also
cultured Enterobacteriaceae and E. coli with specific conditions
and found that both of them indeed dramatically overgrew after
the CAC induction (Figures 6L and 6M). To see whether the
microbiota translocates to the basolateral surface of IECs to acti-
vate TLR signaling for IL-17C production, we performed colon
tissue staining with the antibody for LPS, which exists in gram-
negative bacteria such as E. coli. We observed a strong LPS
signal in the basolateral side of IECs after DSS-mediated epithe-
lial damage (Figure 6N), suggesting that dysregulated Entero-
bacteriaceae, such as E. coli, translocate to the basal area to
induce IL-17C expression in IECs. We next determined whether
CAC-associated E. coli can induce IL-17C expression. DSS plus
E. coli strongly induced IL-17C expression in the mice treated
with the antibiotics to remove the gut microbiota, whereas
E. coli monocolonization alone did not (Figure 6O). Similarly,
DSS plus LPS or DSS plus Flagellin strongly induced IL-17C
expression, whereas the LPS or Flagellin alone did not (Fig-
ure 6O). We further confirmed that E. coli monocolonization
induced IL-17C production in germ-free mice under the DSS
treatment condition (Figure 6P). These data suggest that the
TLR ligands of the dysregulated microbiota can directly induce
IL-17C production in IECs after DSS-mediated epithelial dam-
age. As previously reported (Lupp et al., 2007), we found that
the dysregulated Enterobacteriaceae were almost all E. coli
(data not shown). Similar to the report that E. coli induced IL-
17C expression in the cell line HCT15 (Ramirez-Carrozzi et al.,
2011), we found that E. coli and Enterobacteriaceae dramatically
induced IL-17C expression in both mouse primary IECs and
human colonic epithelial cell lines (Figure 6Q). We also found
that some pathogens and one pathobiont, which belong to
Enterobacteriaceae, induced IL-17C expression but that Lacto-
bacillus did not (Figure S7D), suggesting that not all microbiotas
can induce IL-17C production. Together, our data suggest that
the dysregulation of the commensal E. coli induces IL-17C
expression during colonic tumor development.
Microbiota-Driven IL-17C Production Promotes
Intestinal Tumorigenesis
To determine the contribution of the microbiota to colon tumor
development, we applied a cocktail of antibiotics to the mouse
CAC model and spontaneous intestinal cancer model. The anti-
biotic treatment reduced colon tumor number and tumor load
(Figures 7A and 7B). The antibiotic treatment decreased the tu-
mor number and tumor load in WT mice to the levels of those
of Il17re-deficient mice and did not further reduce tumor number
and tumor load in Il17re-deficientmice in theCACmodel (Figures148 Immunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc.7A and 7B), suggesting that IL-17C is most likely critical for
microbiota-mediated contribution to tumor development. Simi-
larly, in Apcmin/+ mice, the antibiotic treatment decreased spon-
taneous tumor number and tumor load (Figures 7C and 7D) in the
small intestine to numbers similar to those detected in Il17re-
deficient Apcmin/+ mice. To further confirm the role of IL-17C in
mediating microbiota-driven tumor development, we restored
IL-17C expression ectopically in the colon through an adenoviral
system in vivo after the antibiotic treatment. The antibiotic treat-
ment significantly reduced the expression of IL-17C and also the
expression of Bcl-xL and Bcl-2 in the colons (Figure 7E).
Re-expression of IL-17C restored the expression of Bcl-2 and
Bcl-xL (Figure 7E). Furthermore, whereas the antibiotic treatment
reduced tumor formation in the CAC mouse model, the re-
expression of IL-17C restored colon tumor size, tumor number,
and tumor load (Figures 7F–7H). Given that IL-17C promotes
tumorigenesis and that developed tumors can elicit inflamma-
tion, the re-expression of IL-17C also increased production of
proinflammatory genes (Figure 7E). Together, our data suggest
that IL-17C plays a crucial role in microbiota-mediated colon
tumor development.
DISCUSSION
Although the gut microbiota maintains gut homeostasis and is
critical for human health (Hooper et al., 2012), a dysregulatedmi-
crobiota is associated with disease pathogenesis, for example,
in colon cancer (Asquith and Powrie, 2010; Saleh and Trinchieri,
2011). The molecular mechanisms for microbiota-driven tu-
morigenesis remain elusive. Here, we have demonstrated that
IL-17C is critical for microbiota-mediated tumorigenesis. A dys-
regulated microbiota induces IL-17C expression specifically in
IECs. IL-17C in turn promotes intestinal tumor development by
increasing the survival of IECs.
Inflammation has recently been identified as a well-estab-
lished risk factor of colon tumorigenesis and is associated with
CAC development (Grivennikov et al., 2010; Mantovani et al.,
2008). In the chemically induced CAC mouse model, we found
that inflammation unexpectedly increased in Il17re/ mice at
an early stage of tumor development. This enhanced inflamma-
tion was most likely due to the protective role of IL-17C signaling
in control of the gut microbiota because E. coli dramatically
outgrew and removal of microbiota blocked the enhanced
inflammation in Il17re/mice. In contrast to the early increased
inflammation, reduced inflammation was seen in the Il17re/ tu-
mors. It has been reported that developed tumors can elicit
inflammation (Grivennikov et al., 2010; Grivennikov et al.,
2012). Because IL-17C signaling is essential for IEC survival to
promote intestinal tumor development, it is likely that the
reduced inflammation late in the Il17re/ tumors is due to
reduced ‘‘tumor-elicited inflammation.’’ Supporting that notion
in our model, IL-17C-forced tumor development without micro-
biota enhanced inflammation. These data suggest that it is
unlikely that inflammation is the initial cause leading IL-17C
to regulate tumorigenesis, although IL-17C-mediated tumor-
elicited inflammation might contribute to tumor growth at later
stages. Even though inflammatory responses at the beginning
of CAC development upon ablation of IL-17C signaling were
enhanced, this was not sufficient to promote tumor development
Figure 7. Microbiota-Driven IL-17C Production Promotes Tumor Development in the Intestine
(A and B) Colon tumor number (A) and tumor load (B) fromWT (n = 5) or Il17re/ (n = 5) mice and abx-treated WT (n = 5) or Il17re/mice (n = 5) on day 80 of the
CAC model.
(C and D) Tumor number (C) and tumor load (D) from the small intestines of 20-week-oldApcmin/+ (n = 8) orApcmin/+ Il17re/ (n = 8) mice and abx-treatedApcmin/+
(n = 6) or Apcmin/+ Il17re/ (n = 8) mice.
(E) Quantitative mRNA expression of IL-17C, Bcl-2, Bcl-xL, TNFa, IL-6, and Ccl2 in the colons of untreated (N) or abx-treated C57/BL6mice subsequently treated
with the conditions for CAC (T). The empty control virus (Adv-EV) or IL-17C-expressing adenovirus (Adv-IL-17C) was given to the mice multiple times during
stimulation for the CAC (n = 6).
(F) H&E histology of the representative colon tumors of C57/BL6 mice treated as in (E) (1003 magnification).
(G and H) Colon tumor number (G) or tumor load (H) of C57/BL6 mice treated as in (E) (n = 6).
Data are representative of two independent experiments (mean ± SEM in A–E, G, and H). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test.
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Thus, our results suggest that IL-17C-induced IEC survival is
essential for its promotion of intestinal tumor development.
Several studies have shown that dysregulation of the gut mi-
crobiota promotes adenoma development. Germ-free Apcmin/+
mice have reduced small intestinal tumor formation (Dove
et al., 1997), whereas a human colonic commensal promotes co-
lon tumorigenesis in Apcmin/+ mice (Wu et al., 2009). E. coli has
been reported to associate with CRC and contribute to its path-
ogenesis (Arthur et al., 2012; Martin et al., 2004). We found an
outgrowth of E. coli and its associated family, Enterobacteria-
ceae, during intestinal tumorigenesis. These dysregulated bac-
teria strongly induced IL-17C production in both human and
mouse gut epithelial cells. Considering that LPS and Flagellin
can induce IL-17C expression in epithelial cells, IL-17C induction
might not be specific to Enterobacteriaceae. Nevertheless, onlyGammaproteobacteria were outgrown among the four major in-
testinal bacterial phyla, and it is likely that the colon-cancer-
associated Enterobacteriaceae, particularly E. coli, are mainly
responsible for IL-17C induction. We have provided evidence
that monocolonization of E. coli can strongly induce IL-17C
expression. The microbiota is sensed by TLRs. We also found
that the dysregulated microbiota translocated to the basolateral
side of IECs after DSS treatment; this is most likely important for
the dysregulated microbiota to activate TLR signaling in IECs
because E. coli or TLR ligands induced IL-17C expression only
after DSS treatment. MyD88 is a key signaling adaptor inmultiple
TLR signaling, as well as in IL-1b and IL-18 signaling, and is
critical for IL-17A production during colon tumor development
(Grivennikov et al., 2012). We found that in addition to being
important for the regulation of IL-17A, MyD88 was critical for
IL-17C induction during intestinal tumorigenesis. Data from BMImmunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc. 149
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rather than in hematopoietic cells was required for IL-17C induc-
tion, whereas MyD88 expression in hematopoietic cells was
essential for IL-17A induction, indicating that the dysregulated
microbiota directly induces IL-17C expression in IECs and that
IL-17C and IL-17A are differentially regulated. Notably, we found
that microbiota-driven IL-17A, but not IL-17C, production
required ASC and CASP1, which are components of the inflam-
masome complex and essential for maturation of IL-1b and
IL-18, further confirming that IL-17C and IL-17A are differentially
regulated and indicating that TLR-MyD88 signaling is respon-
sible for microbiota-driven IL-17C induction. Antibiotic treatment
to remove the microbiota dramatically reduces IL-23 production
and consequently IL-17A production during colon tumorigenesis
(Grivennikov et al., 2012). Here, we found that antibiotic treat-
ment also severely diminished IL-17C production and intestinal
tumor development but that ectopically re-expression of
IL-17C restored tumor formation, suggesting that IL-17C con-
tributes to microbiota-driven tumorigenesis. We observed that
IL-17C can induce expression of antiapoptotic factors (Bcl-xL
and Bcl-2) in colon epithelial cells in vitro. Consistent with the
blockage of IL-17C induction, microbiota depletion reduced
the expression of the genes encoding Bcl-xL and Bcl-2, whereas
ectopic expression of IL-17C expression restored the expression
of the survival genes. In addition, forced re-expression of Bcl-xL
and Bcl-2 in Il17re-deficient mice restored tumor formation.
These data suggest that IL-17C mediates microbiota-driven
tumorigenesis by enhancing IEC survival.
Tumor-promoting cytokines are mainly produced by inflam-
matory immune cells, which are recruited to the tumor microen-
vironment (Grivennikov et al., 2010). IL-17A is produced by
hematopoietic-derived cells, such as Th17 cells and some innate
lymphocytes (Cua and Tato, 2010; Zhu and Qian, 2012). The
hematopoietic IL-23-Th17-IL-17A axis contributes to micro-
biota-driven tumor growth. Here, we found that IL-17C also
contributed to microbiota-mediated tumorigenesis. However,
IL-17C regulation was different from that of IL-17A. IL-17C was
specifically induced in IECs. IL-23, a cytokine critical for Th17
cell development, has been shown to be critical for IEC prolifer-
ation, but not survival, during intestinal tumorigenesis (Grivenni-
kov et al., 2012). Similarly, we found that IL-17A was required for
IEC proliferation, but not survival. In contrast, IL-17C was essen-
tial for IEC survival, but not proliferation, during an early stage of
tumor development. These data demonstrate that IL-17C and
IL-17A are differentially regulated and play differential and nonre-
dundant roles in intestinal tumor development. Although IL-17C
has been reported to promote Th17 cell development in vitro
(Chang et al., 2011), our BM transplantation experiments
showed that the intestinal local resident cells rather than he-
matopoietic cells were critical for IL-17C-mediated tumorigen-
esis, suggesting that IL-17C-mediated IEC survival rather than
its effect on Th17 cell development is crucial for promoting
tumorigenesis. In addition, we found that IL-17C was induced
much earlier than IL-17A during colon cancer development.
Thus, both IL-17C produced early by IECs and IL-17A produced
late by infiltrated Th17 cells in the gut promote intestinal tumor
formation.
In summary, we have identified IL-17C as a critical early cyto-
kine that promotes intestinal tumor development. IL-17C is150 Immunity 40, 140–152, January 16, 2014 ª2014 Elsevier Inc.induced in IECs directly by the dysregulated microbiota and in
turn mediates microbiota-driven tumorigenesis by promoting
IEC survival. Our study provides a mechanism for microbiota-
mediated tumor development through IL-17C regulation and
suggests that IL-17C is a potential promising new target for
cancer therapy.
EXPERIMENTAL PROCEDURES
Human Samples
All human tissues were obtained from the Tumor Center at the Shanghai Insti-
tute of Health Sciences. All individuals provided informed consent. The study
was approved by the institutional biomedical research ethics committee of the
Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences).
Mice
Il17re/mice were from ZymoGenetics, as previously described (Song et al.,
2011).Myd88/mice were kindly provided by Dr. Jiong Deng (Shanghai Jiao-
tong University). Il17a/mice were a gift from Dr. Yoichiro Iwakura (University
of Tokyo). Il17re/, Il17a/, and Myd88/ mice and their representative
littermate control mice were utilized for the experiments. Asc/ mice were
kindly provided by Dr. Vishva Dixit (Genentech). Caspase1/ mice were
from Jackson Laboratory. All of the above mice were maintained in specific
pathogen-free conditions. Germ-free mice were obtained from Shanghai
SLAC Laboratory Animal Co. All animal studies were performed in compliance
with the guide for the care and use of laboratory animals andwere approved by
the institutional biomedical research ethics committee of the Shanghai Insti-
tutes for Biological Sciences.
Induction of CAC and Spontaneous Intestinal Cancer
Il17re/ and WT littermate mice were injected with AOM (Sigma) intraperito-
neally. After 5 days, mice were given 2.5% DSS in drinking water, followed by
regular water for 16 days. This cycle was repeated twice (mice were given
2.0% DSS for 4 days in the third cycle). Mice were sacrificed for tumor and
tissue analyses on day 80 of the experiments.
Sex-matched Apcmin/+Il17re+/+ and Apcmin/+Il17re/ littermates were
allowed to develop colorectal tumors spontaneously for 20 weeks and then
killed for tumor and tissue analysis.
Statistics
Data are presented as themean ± SEM. A two-tailed Student’s t test was used
for analysis of the differences between the groups. p values < 0.05 were
considered statistically significant.
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